Evotec SE is a prominent global biotechnology company headquartered in Hamburg, Germany, specializing in delivering comprehensive drug discovery and development solutions to the pharmaceutical and biotech industries. The firm is distinguished by its collaborative strategy, forming partnerships with leading pharmaceutical entities and prestigious academic institutions to accelerate the progress of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline, Evotec is strategically positioned to leverage new opportunities within the biopharmaceutical sector, reaffirming its essential contribution to healthcare innovation and improved patient outcomes.
| Revenue (TTM) | $717.28M |
| Gross Profit (TTM) | $60.71M |
| EBITDA | $-73.18M |
| Operating Margin | -62.30% |
| Return on Equity | -26.10% |
| Return on Assets | -5.39% |
| Revenue/Share (TTM) | $2.02 |
| Book Value | $2.15 |
| Price-to-Book | 0.73 |
| Price-to-Sales (TTM) | 0.76 |
| EV/Revenue | 0.684 |
| EV/EBITDA | 34.36 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -16.20% |
| Shares Outstanding | $355.39M |
| Float | $270.77M |
| % Insiders | 0.01% |
| % Institutions | 0.81% |
Volatility is currently expanding
Evotec faces deteriorating fundamentals, with 1H26 revenue down nearly 20% and adjusted EBITDA turning sharply negative. I have withdrawn confidence in management's targets; valuation is now strictly on an as-is basis, with no credit given for future guidance. Despite a strong liquidity position and some commercial momentum, profitability remains elusive, and turnaround timelines have been pushed out.
First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies Program Supports development of countermeasures against orthopoxviruses, a high-priority biological threat family that includes viruses responsible for smallpox Delivers integrated process development, regulatory submission and manufacturing of clinical trial material at J.POD® Redmond facility Demonstrates scalable model for development and continuous manufacturing for biodefense preparedness SEATTLE and HAMBURG, Germany, Sept. 9, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its biologics CDMO subsidiary Just – Evotec Biologics under the U.S. Department of War's Accelerated Antibodies Program.
Collaboration aims to validate Evotec's proprietary BiTco costimulatory CD2 bispecifics platform in combination with Plectonic's logic-gated DNA-protein immunotherapy technology LOGIBODY® BiTco designed to boost T cell activation by engaging a costimulatory signaling pathway LOGIBODY® designed to enhance precision of T cell activation based on multispecific antigen signature HAMBURG, Germany and HALLBERGMOOS, Germany, Sept. 2, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors.
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need HAMBURG, Germany, Aug. 6, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics, Inc. (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreement, Odyssey will leverage Evotec's integrated data-driven discovery platform, advanced screening capabilities and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across multiple high-value disease targets.
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD Pharmaceuticals Corp., N.
PALO ALTO, Calif.--(BUSINESS WIRE)--Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. A life science company that is pioneering the future of drug discovery and development, Evotec had historically managed T&E independentl.
Evotec SE (EVO) Q2 2026 Earnings Call Transcript
Evotec NASDAQ: EVO reported preliminary unaudited results for the second quarter and first half of 2026 and lowered its full-year outlook, citing delayed strategic partnership revenue, slower conversion of commercial activity into revenue and longer timelines for new partnership agreements.
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 HAMBURG, Germany, July 13, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for the second quarter and first half of 2026 and updated its full-year 2026 outlook.
Expands Just – Evotec Biologics partner-enablement and technology licensing model for proprietary continuous manufacturing platform Enables deployment of continuous manufacturing platform in partner-owned facilities to support higher productivity and flexibility compared with fed-batch technology biologics manufacturing Modular manufacturing infrastructure, equipment and proprietary technology enable rapid and cost-efficient increase in capacity for biologics manufacturing SEATTLE and HAMBURG, Germany, June 30, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the expansion of its Just – Evotec Biologics services with J.TRAIN, a new offering that enables biopharmaceutical companies to deploy Evotec's proprietary continuous manufacturing technology directly within their own facilities on a turnkey basis. J.TRAIN brings together prefabricated modular cleanrooms and industry-standard manufacturing equipment with Just – Evotec Biologics' cGMP-compliant process automation, designed to enable significantly faster and more cost-effective deployment than traditional manufacturing expansion.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EVO and any ticker you trade — then tracks every position and per-strategy win rate.
